Physician profile
Ashley See
NPI 1467892380
$2,415.01
in general payments reported to CMS, 2019-2025
27 companies · $1,155 in 2025
The $1,155 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $212 · 2022: $256 · 2023: $372 · 2024: $420 · 2025: $1,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,947.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $665.16 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $324.41 | 2021-2025 | |
| Lilly USA, LLC | $211.95 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $200.03 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Verona Pharma, INC. | $179.64 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $99.08 | 2025 | Yupelri |
| Genzyme Corporation | $95.83 | 2025 | |
| Amgen INC. | $69.92 | 2024-2025 | Tezspire, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $66.29 | 2025 | Airsupra, Fasenra |
| Biohaven Pharmaceutical Holding Company LTD. | $53.01 | 2022 | |
| Grifols USA, LLC | $52.07 | 2025 | Prolastin-C Liquid |
| Otsuka America Pharmaceutical, INC. | $51.75 | 2023-2024 | Rexulti |
| Genentech USA, INC. | $37.37 | 2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $32.16 | 2025 | Glassia |
| Pfizer INC. | $29.35 | 2023-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $28.18 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $26.94 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $26.09 | 2023 | |
| Inspire Medical Systems, INC. | $24.99 | 2025 | Inspire |
| Axsome Therapeutics, INC. | $24.80 | 2025 | Sunosi |
| Philips North America LLC | $23.30 | 2025 | Vest Therapy Und |
| Insmed, INC. | $18.44 | 2025 | Brinsupri, Arikayce |
| Esperion Therapeutics, INC. | $17.09 | 2021 | |
| United Therapeutics Corporation | $16.44 | 2025 | Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.77 | 2023 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.10 | 2024 | Caplyta |
| Amarin Pharma, INC. | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley See listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.